Low‑dose sirolimus in retroperitoneal lymphangioleiomyomas.

Lymphangioleiomyomatosis (LAM) is a rare disease associated with cystic lung destruction and abdominal tumors, including lymphangioleiomyomas, which frequently occur in the retroperitoneal region. Sirolimus therapy is currently recommended for LAM patients with abnormal or declining lung function with an adjusted dose to maintain a serum trough level of 5–15 ng/mL. We describe a significant reduction of retroperitoneal lymphangioleiomyomas after treatment with low‑dose sirolimus therapy (serum trough level <5 ng/mL) in a patient with sporadic LAM. [ABSTRACT FROM AUTHOR]